Antihypertensive treatment and risk of cardiovascular mortality in patients with chronic kidney disease diagnosed based on the presence of proteinuria and renal function: A large longitudinal study in Japan

Kei Nagai1, Kunihiro Yamagata1,2*, Kunitoshi Iseki2,3, Toshiki Moriyama2,4, Kazuhiko Tsuruya2,5, Shouichi Fujimoto2,6, Ichie Narita2,7, Tsuneo Konta2,8, Masahide Kondo1,2, Masato Kasahara2,9, Yugo Shibagaki2,10, Koichi Asahi2,11, Tsuyoshi Watanabe1,2

1 University of Tsukuba, Tsukuba, Ibaraki, Japan, 2 The Steering Committee for “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment by Specific Health Checkups”. Tsukuba, Ibaraki, Japan, 3 Okinawa Heart and Renal Association, Okinawa, Japan, 4 Health Care Center, Osaka University, Suita, Japan, 5 Nara Medical University, Nara, Japan, 6 University of Miyazaki, Miyazaki, Japan, 7 Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 8 Yamagata University Graduate School of Medical Science, Yamagata, Japan, 9 Institute for Clinical and Translational Science, Nara Medical University Hospital, Nara, Japan, 10 St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan, 11 Iwate Medical University, Morioka, Japan, 12 Fukushima Rosai Hospital, Iwaki, Japan

* k-yamaga@md.tsukuba.ac.jp

Abstract

Several recent clinical trials and meta-analyses have shown that lowering blood pressure reduces the risk of cardiovascular disease. However, current evidence that describes general demographics in blood pressure and mortality with chronic kidney disease is sparse in Japan. Using a population-based longitudinal cohort that received annual health checkups in Japan in 2008, hypertensive status, self-reported use of antihypertensive drugs, and prognosis were examined through 2012. Chronic kidney disease was defined as positive proteinuria or estimated glomerular filtration rate <60 ml/min/1.73 m². Subjects were 40 to 74 years old (n = 227,204) with median 3.6 years follow-up period, and patients with and without chronic kidney disease were analyzed separately (n = 183,586 and n = 43,618, respectively). Cardiovascular disease mortality, comprising coronary heart diseases and stroke as entered in the national death registry using ICD-10 coding, was examined. Among all subjects, 346 deaths (96 in chronic kidney disease and 250 in non-chronic kidney disease) due to cardiovascular disease occurred. Compared with cardiovascular disease mortality in chronic kidney disease patients with untreated normal blood pressure, the multivariable adjusted hazard ratio was 3.08 (95% confidence interval: 1.75–5.41) for those with untreated hypertension, 2.30 (1.31–4.03) for those who became normotensive after treatment, and 3.28 (1.91–5.64) for those who remained hypertensive despite treatment. In non-chronic kidney disease subjects, the ratios were 1.90 (1.33–5.41), 1.95 (1.35–2.80), and 1.77 (1.18–2.66), respectively. These results from a nationwide cohort could be one of
representative demographics of controlling blood pressure and cardiovascular disease deaths when treating patients with chronic kidney disease in Japan in recent years. Even after development and spread of anti-hypertensive drugs, preventing development of hypertension is preferable, because any hypertension treatment status comparing untreated normal blood pressure was a risk of cardiovascular mortality at baseline year.

Introduction

High blood pressure (BP) confers a risk of cardiovascular disease (CVD) [1–3]. Compared with the general population, patients with chronic kidney disease (CKD) have a high risk of CVD mortality [4]. Guidelines recommend lower BP targets in the CKD population than in the general population to slow the progression of CKD [5,6]. Antihypertensive therapy is well known to reduce CVD risk in the general population [7,8]. However, there is little evidence regarding BP treatment and CVD death in patients with CKD.

Numerous observational studies focused on general populations have found that, for a given baseline BP, the risk of CVD is higher for people who use antihypertensive medications than for those who do not [1,9–14]. However, most of them failed to consider participants' renal function and proteinuria, which are well-known determinants of cardiovascular risk, because the cohorts were established decades ago, before the current definitions of CKD were developed. A recent meta-analysis of data from randomized, controlled trials showed the effectiveness of BP reduction by antihypertensive medications [15]. However, systematic searches of 123 randomized trials demonstrated that only a few reported the renal function of the cohort. For example, of 31 BP-lowering trials assessing different BP targets, only 6 studies selected cohorts that included CKD patients [16–21], whereas 12 studies defined no-CKD cohorts, and the remaining 13 did not report the renal function of their cohorts. These results also indicate the rarity of longitudinal cohorts that include a well-identified CKD population for assessing CVD mortality.

The present study evaluated a longitudinal, general-population cohort of 227,204 persons who received annual health checkups, including examinations for proteinuria and renal function according to “The Specific Health Check and Guidance in Japan” program in 2008, and followed their prognosis and cause of death through December 2012. In subpopulations with and without CKD diagnosed based on the presence of proteinuria and renal function, risks for all-cause and CVD mortality were examined among various categories of BP control. This analysis provides information about the representative status of BP control and CVD mortality of Japanese people with CKD in recent years.

Methods

Patients and methods

This longitudinal cohort study was conducted according to the guidelines of the Declaration of Helsinki and was granted ethics approval by the relevant institutional review boards (University of Tsukuba for ethical issues approved as No. 999, UMIN: 000019774). Original Ethics Committee approval was obtained from Fukushima Medical University (IRB #1485, #2771).

The study was performed as part of the prospective ongoing "Research on the Positioning of Chronic Kidney Disease in Specific Health Check and Guidance (so-called “Tokutei-Ken-shin”) in Japan” project [22]. Other details, such as the participants’ areas of residence, were
reported previously [23–25]. Outliers were deleted through winsorization; they accounted for 0.01%–0.1% of the total. The raw database was solely used and managed by the statistician, and the principal analyses to identify those who died among screened subjects were completed by March 2015 and recently reported [26]. Subsequent analyses were done using a standard analysis file (SAF) without any personal identifiers.

The duration of follow-up of the subjects was 1 to 4 years (2008 through 2012, median duration was 3.6 years). The net subject population comprised 227,204 people (59.0% [n = 134,103] were women) aged from 40 to 74 years and for whom all of the data necessary for our research purposes were available. The data included information about age, sex, body mass index (BMI), systolic BP, diastolic BP, smoking habit, use of antihypertensive, lipid-lowering, and hypoglycemic drugs (obtained by self-reported questionnaire), and the results of dipstick urinalyses for proteinuria and blood tests for glucose levels, creatinine concentration, and lipid status.

**Mortality surveillance**

The underlying causes of death were coded according to ICD-10. Follow-up was conducted through December 2012. Incidents of CVD death were defined by ICD coding as I20-29 and I60-69.

**Measurement of parameters**

Urinalysis by the dipstick method was performed on a single spot-urine specimen collected early in the morning. Urine dipstick results for proteinuria were interpreted by the medical staff at each local medical institution and recorded as −, +/−, 1+, 2+, and 3+. In Japan, the Japanese Committee for Clinical Laboratory Standards (http://jccls.org/) recommends that all urine dipstick results of 1+ correspond to a urinary protein level of 30 mg/dl; proteinuria was defined as 1+ or greater. Serum creatinine was measured using the enzymatic method. The glomerular filtration rate (GFR) was estimated using the formula of the Japanese Society of Nephrology [27]. CKD was defined as positive proteinuria or estimated GFR (eGFR) <60 ml/min/1.73 m². Hyperglycemia was defined as HbA1c ≥6.5%, and hypertension was defined as systolic BP ≥140 mmHg and diastolic BP ≥90 mmHg. Hypercholesterolemia was defined as low-density lipoprotein cholesterol ≥140 mg/dl, high-density lipoprotein cholesterol ≤40 mg/dl, or triglycerides ≥200 mg/dl. These comorbid conditions at the baseline year were used for the risk analysis.

**Statistical analysis**

The primary outcomes for the analysis were all-cause and CVD deaths during the follow-up period. Variables were age, sex, HbA1c, hypertension, renal function, proteinuria, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglycerides, cigarette smoking, use of antihypertensive medication, use of lipid-lowering drugs, and treatment for diabetes. The hypertension treatment category was defined according to BP levels (normal, <140/<90 mmHg; hypertensive, ≥140/≥90 mmHg), as directed in the hypertension guidelines [28]. When the systolic and diastolic BPs were in different categories, the subject was assigned to the hypertension treatment category. After subjects were categorized according to BP, they were allocated to untreated normal, untreated hypertensive, treated normotensive, and treated hypertensive groups. Hazard ratios of the incidence of CVD were estimated using the Cox regression model (SAS version 9.4, SAS Institute, Cary, NC, USA). Other statistical analyses and graphical analyses were performed using Stata version 14 and GraphPad Prism version 6. A P value <0.05 was considered significant.
Results

Table 1 presents the mean ages of the subjects and the means and proportions of risk factors at the baseline year, according to hypertension treatment category. Compared with subjects with untreated, normal BP at baseline, untreated hypertensive subjects were a mean of 2.4 years older, and the treated population was 5.5 years older on average; in addition, BMI was higher in hypertensive subjects, regardless of treatment category. Furthermore, eGFR was 1.3 ml/min/1.73 m$^2$ lower in the subpopulation with untreated hypertension and 5 ml/min/1.73 m$^2$ lower in subjects who remained hypertensive despite treatment, compared with that of subjects with untreated normal BP. The rate of positive proteinuria was higher in hypertensive than in normotensive subjects, and those with treated hypertension had the highest rate of positive proteinuria. The use of lipid-lowering drugs and of diabetes treatment paralleled that of hypertensive drugs. Finally, the rate of cigarette smoking was lower in treated than in untreated populations.

The characteristics of subjects with and without CKD are shown in Table 2. The trends in mean age, BMI, eGFR, and proportions of positive proteinuria, medication use, and cigarette smoking between subjects with and without CKD (Table 2) paralleled those between hypertension treatment categories (Table 1). Within a hypertension treatment category, subjects with CKD tended to include fewer women and have a higher mean age, higher BMI, worse dyslipidemia and hyperglycemia and a higher rate of positive proteinuria than did those without CKD (Table 2).

During follow-up, 2745 all-cause deaths (2107 non-CKD subjects and 638 CKD subjects) and 346 CVD deaths (250 non-CKD subjects and 96 CKD subjects) occurred in this cohort. The all-cause mortality and CVD mortality in subjects with and without CKD according to proteinuria and renal function are shown in Table 3. Dividing the number of all-cause deaths by the person-years at risk yields the all-cause mortality rate and CVD mortality rate per 1000 person-years at risk. The rates of all-cause death and CVD death were lower in non-CKD subjects than in CKD subjects.

Table 1. Study population.

|                      | Normotensive Un treated | Hypertensive Un treated | Normotensive Treated | Hypertensive Treated | P   |
|----------------------|-------------------------|-------------------------|----------------------|----------------------|-----|
| Number               | 127,312                 | 37,867                  | 34,662               | 27,363               |     |
| Sex                  |                         |                         |                      |                      |     |
| %, women             | 63.4                    | 52.9                    | 56.6                 | 53.2                 | <0.001|
| Age                  |                         |                         |                      |                      |     |
| years                | 60.4 ± 9.4              | 62.8 ± 8.2              | 65.9 ± 6.4           | 65.9 ± 6.5           | <0.001|
| Height               |                         |                         |                      |                      |     |
| cm                   | 157.2 ± 8.4             | 157.5 ± 8.8             | 156.0 ± 8.4          | 156.4 ± 8.6          | <0.001|
| Weight               |                         |                         |                      |                      |     |
| kg                   | 56.0 ± 10.0             | 59.3 ± 10.9             | 59.4 ± 10.4          | 60.9 ± 10.8          | <0.001|
| Body mass index      |                         |                         |                      |                      |     |
| kg/m$^2$             | 22.6 ± 3.1              | 23.8 ± 3.3              | 24.3 ± 3.3           | 24.8 ± 3.5           | <0.001|
| Systolic blood pressure |                       |                         |                      |                      |     |
| mmHg                 | 118.9 ± 12.0            | 148.9 ± 12.8            | 126.2 ± 9.0          | 149.3 ± 11.5         | <0.001|
| Diastolic blood pressure |                     |                         |                      |                      |     |
| mmHg                 | 71.7 ± 8.5              | 86.9 ± 9.8              | 74.7 ± 7.8           | 84.8 ± 9.5           | <0.001|
| Triglycerides        |                         |                         |                      |                      |     |
| mg/dl                | 112 ± 76                | 132 ± 96                | 125 ± 76             | 133 ± 89             | <0.001|
| High-density lipoprotein |                   |                         |                      |                      |     |
| mg/dl                | 63 ± 16                 | 61 ± 16                 | 59 ± 15              | 59 ± 15              | <0.001|
| Low-density lipoprotein |                  |                         |                      |                      |     |
| mg/dl                | 126 ± 31                | 129 ± 32                | 120 ± 28             | 123 ± 29             | <0.001|
| HbA1c                |                         |                         |                      |                      |     |
| %                    | 5.3 ± 0.6               | 5.4 ± 0.8               | 5.5 ± 0.7            | 5.5 ± 0.8            | <0.001|
| eGFR                 |                         |                         |                      |                      |     |
| ml/min/1.73 m$^2$    | 75.8 ± 15.5             | 74.5 ± 15.9             | 70.8 ± 16.2          | 71.0 ± 16.3          | <0.001|
| Proteinuria          |                         |                         |                      |                      |     |
| %, + or more         | 3.2                     | 6.7                     | 7.8                  | 11.2                 | <0.001|
| Use of antihypertensive drugs |              |                         |                      |                      |     |
| %, yes               | 0                       | 0                       | 100                  | 100                  | –    |
| Lipid-lowering drug use |                     |                         |                      |                      |     |
| %, yes               | 8.8                     | 7.4                     | 28.8                 | 26.0                 | <0.001|
| Diabetes treatment   |                         |                         |                      |                      |     |
| %, yes               | 3.0                     | 3.1                     | 9.4                  | 10.4                 | <0.001|
| Cigarette smoking    |                         |                         |                      |                      |     |
| %, yes               | 14.4                    | 14.3                    | 10.8                 | 10.6                 | <0.001|

Low eGFR; less than 60 ml/min/1.73 m$^2$

https://doi.org/10.1371/journal.pone.0225812.t001
mortalities and CVD deaths in each hypertension treatment category by the total number of subjects in that subpopulation showed increased rates of both all-cause and CVD mortalities in these subjects, regardless of their CKD status, compared to subjects with untreated, normal BP (Table 3).

Table 2. Baseline characteristics of subpopulations with and without chronic kidney disease (CKD).

| CKD (-) | Normotensive | Hypertensive | Normotensive | Hypertensive | P  |
|---------|--------------|--------------|--------------|--------------|----|
| Number  | 108653       | 30341        | 25236        | 19356        |    |
| Sex     | %, women     |              |              |              |    |
| Age     | years        |              |              |              |    |
| Height  | cm           |              |              |              |    |
| Weight  | kg           |              |              |              |    |
| Body mass index | kg/m² |              |              |              |    |
| Systolic blood pressure | mmHg |              |              |              |    |
| Diastolic blood pressure | mmHg |              |              |              |    |
| Triglycerides | mg/dl     |              |              |              |    |
| High-density lipoprotein | mg/dl |              |              |              |    |
| Low-density lipoprotein | mg/dl |              |              |              |    |
| HbA1c % |              |              |              |              |    |
| eGFR ml/min/1.73 m²² |              |              |              |              |    |

| CKD (+) |
|---------|
| Number  | 18659       | 7526        | 9426         | 8007         |    |
| Sex     | %, women     |              |              |              |    |
| Age     | years        |              |              |              |    |
| Height  | cm           |              |              |              |    |
| Weight  | kg           |              |              |              |    |
| Body mass index | kg/m² |              |              |              |    |
| Systolic blood pressure | mmHg |              |              |              |    |
| Diastolic blood pressure | mmHg |              |              |              |    |
| Triglycerides | mg/dl     |              |              |              |    |
| High-density lipoprotein | mg/dl |              |              |              |    |
| Low-density lipoprotein | mg/dl |              |              |              |    |
| HbA1c % |              |              |              |              |    |
| eGFR ml/min/1.73 m²² |              |              |              |              |    |

Low eGFR; less than 60 ml/min/1.73 m²²

https://doi.org/10.1371/journal.pone.0225812.t002
The hazard ratio (HR) for all-cause mortality in each hypertensive status is shown in Fig 1. Subjects with and without proteinuria (Fig 1A) or low eGFR (Fig 1B) and those with and without CKD were analyzed separately, regardless of how the condition was defined (i.e., “overall CKD”) (Fig 1C). Using the untreated normotensive subpopulation as a reference, the risk of all-cause mortality among patients with proteinuria was significantly increased among those with untreated hypertension (age- and sex-adjusted HR, 1.38 [95% confidence interval 1.01–1.89]; multivariable-adjusted HR, 1.45 [1.06–1.99]; Fig 1A). However, among subjects with low eGFR (Fig 1B) and those with overall CKD (Fig 1C), the HR for all-cause mortality did not differ significantly between subjects with untreated normotension and those with untreated hypertension, those who became normotensive during treatment, or those who remained hypertensive despite treatment. Overall, analyses for all-cause mortality risk did not identify hypertensive status as an independent risk factor in subjects diagnosed with CKD according to the presence of proteinuria or decreased renal function.

In contrast to all-cause mortality, relative to those for the subpopulation with untreated normal BP, the adjusted HRs for CVD mortality in subjects without proteinuria, without low eGFR, and without CKD showed significance (Fig 2). Moreover, HRs for CVD mortality in subjects with CKD were mostly significant and varied widely in each hypertension treatment category (filled circles in Fig 2): from 2.12 to 4.61 in subjects with proteinuria, from 2.27 to 3.08 in those with low eGFR, and from 2.30 to 3.28 in those with overall CKD. Summarizing the above, these analyses identified every hypertension treatment category as a risk factor for CVD mortality both in non-CKD and in CKD status, independent of well-known CVD risk factors, such as age, sex, BMI, and cigarette smoking.
Discussion

When compared with the general population, patients with CKD are at increased risk for CVD mortality \[4,29\]. General-population-based observational studies have shown that, for a
given BP at baseline, CVD risk is higher in subjects who use antihypertensive medications than in those who do not [9–14]. Although the cohorts in the cited studies were well defined and rigorously followed, all of the cohorts were established decades ago (i.e., 1970 [9,10], 1991.

Fig 2. Risk of all cardiovascular mortality in each hypertension treatment category. The multivariable-adjusted hazard ratio and 95% confidence interval for cardiovascular mortality in each hypertensive treatment category are shown. The reference category is untreated, normal blood pressure. The subgroups reflect the presence (or absence) of proteinuria (A), reduced renal function (B), and chronic kidney disease (C). Adjusted factors for death were: age; sex; cigarette smoking; body mass index; proteinuria; levels of triglycerides, high-density lipoprotein, and low-density lipoprotein; use of lipid-lowering drugs; HbA1c; and treatment for diabetes.

https://doi.org/10.1371/journal.pone.0225812.g002
through 1998 [11], 1967 through 1996 [13], and 1991 through 1996 [14]). In addition, their results were evaluated in the context of then-contemporary clinical practice. Therefore, most of the evidence [2,30–34] does not take into consideration the renal function of the participants, because the cohorts were also built without the conception of CKD from Kidney Disease: Improving Global Outcomes (KDIGO) in 2002 [6]. Because the timing and breadth of the recruitment might affect the characteristics of cohort subjects because of changes in clinical practice regarding the treatment of hypertension, use of a cohort with well-identified renal function and consistent baseline year data facilitates assessment of the relationship between BP control at baseline and CVD mortality in patients with CKD.

In this analysis, a general-population-based cohort established in 2008 was examined for which data regarding proteinuria, renal function, other CVD risk factors, and ICD-coded cause of death were available. In this cohort, age, risks, and proportions of patients at baseline year differed significantly between subjects with untreated normal BP and those in other hypertension treatment categories. Because ageing is associated with a decline in eGFR and increases in BP and the rate of positive proteinuria [35], the older age and lower eGFR seen in treated or hypertensive subjects are unsurprising (Table 1). Similarly, within the same hypertension treatment category, subjects with CKD tended to be older than those without CKD (Table 2).

Previous Japanese general-population–based cohorts established from 1980 through 1995 [2, 31–34] comprised 27.4% with untreated hypertension. Research and development in anti-hypertensive drugs has been remarkable. As examples, angiotensin-converting enzyme inhibitors began to be prescribed in 1982 to 1998 and angiotensin receptor blockers began in 1998 to 2012, and their market share in Japan continues to grow. Our investigation shows the rate of untreated hypertension was subjects with CKD (17.3%) than those without CKD (16.5%), suggesting successful spread of anti-hypertensive drugs in recent years (Table 2).

A collaborative prospective meta-analysis of randomized trials to examine the cardiovascular effects of lowering BP in people with CKD according to renal function [36], which covers 152,290 participants, including 30,295 with eGFR < 60 ml/min/1.73 m². Another [15] performed a meta-analysis of systematic searches of BP-lowering trials to examine the effects of a 10-mmHg reduction in systolic BP on the relative risk of major CVD in 30,766 participants from 18 cohorts. However, neither of these previous studies [15,36] directly showed the effect of BP reduction in patients with proteinuria. Though our study could not show any effect of interventional BP control on CVD mortality in patients with proteinuria, markedly high HR (4.61) in untreated hypertension category for CVD mortality in positive proteinuria population implies importance of BP control in such patients (Fig 2A).

The strength of this study was that it evaluated a large general population (i.e., more than 100,000 subjects) with available data regarding renal function, proteinuria, and CVD (i.e., stroke and cardiac events) mortality according to ICD-10 coding. These features allowed us to perform sub-analyses of the CKD and non-CKD subjects enrolled, showing that the risk of CVD in patients who remained hypertensive despite treatment differed between those with and without CKD, between those with and without proteinuria, and between those with and without low eGFR.

However, this study had several limitations. First, the database did not have details of the types of antihypertensive drugs used, such as renin-angiotensin-targeted drugs, which affect the incidence of CVD [37], because this information was self-reported and not obtained through medical records or claims. Second, the follow-up time (maximum, 4 years) was much shorter than in previous studies. Because this observational study could not show cause/result relationship, evidence for interventional benefit of BP control was not obtained.

Nevertheless, the results from a nationwide cohort could be one of representative demographics of controlling blood pressure and cardiovascular disease deaths when treating...
patients with CKD in Japan in recent years. Even after current development and sufficient spread of anti-hypertensive drugs, preventing development of hypertension is preferable, because any hypertension treatment status comparing untreated normal blood pressure was a risk of CVD mortality at baseline year.

Acknowledgments
This study would not have been possible without the generous support from the public health nurses of the Kokuho agency in each district. This study was supported in part by a grant for Development of Comprehensive Database of Chronic Kidney Disease, Research on Policy Planning and Evaluation from the Ministry of Health, Labor and Welfare of Japan.

Author Contributions
Conceptualization: Kei Nagai, Kunihiro Yamagata, Kunitoshi Iseki, Koichi Asahi, Tsuyoshi Watanabe.
Funding acquisition: Kunihiro Yamagata.
Investigation: Kei Nagai, Kunihiro Yamagata, Kunitoshi Iseki, Koichi Asahi, Tsuyoshi Watanabe.
Methodology: Kei Nagai, Kunihiro Yamagata, Kunitoshi Iseki, Koichi Asahi, Tsuyoshi Watanabe.
Supervision: Kunihiro Yamagata, Kunitoshi Iseki, Tsuyoshi Watanabe.
Visualization: Kei Nagai.
Writing – original draft: Kei Nagai.
Writing – review & editing: Kunihiro Yamagata, Kunitoshi Iseki, Toshiki Moriyama, Kazuhiko Tsuruya, Shouichi Fujimoto, Ichiei Narita, Tsuneo Konda, Masahide Kondo, Masato Kasahara, Yugo Shibagaki, Koichi Asahi, Tsuyoshi Watanabe.

References
1. Asayama K, Ohkubo T, Yoshida S, Suzuki K, Metoki H, Harada A, et al. Stroke risk and antihypertensive drug treatment in the general population: the Japan arteriosclerosis longitudinal study. J Hypertens. 2009; 27: 357–364. https://doi.org/10.1097/HJH.0b013e32831967ca PMID: 19155790
2. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med. 2003; 163: 361–366. https://doi.org/10.1001/archinte.163.3.361 PMID: 12578518
3. Ikeda A, Iso H, Yamagishi K, Inoue M, Tsugane S. Blood pressure and the risk of stroke, cardiovascular disease, and all-cause mortality among Japanese: the JPHC Study. Am J Hypertens. 2009; 22: 273–280. https://doi.org/10.1038/ajh.2008.356 PMID: 19229210
4. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375: 2073–2081. https://doi.org/10.1016/S0140-6736(10)6074-5 PMID: 20483481
5. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42: 1206–1252. https://doi.org/10.1161/01.HYP.0000107251.49515.C2 PMID: 14656957
6. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1–266. PMID: 11904577
7. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001; 358: 1305–1315. https://doi.org/10.1016/S0140-6736(01)06411-X PMID: 11684211
Iseki K, Asahi K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, et al. Risk factor profiles based on ...

Ogihara T. Practitioner’s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension...

Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium ...

Izumi M, Suzuki K, Sakamoto T, Hayashi M. Advantages and limitations of antihypertensive treatment...

Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease ...

Sato Y, Yano Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Glycohemoglobin not as predictive as ...

Yano Y, Sato Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Association of high pulse pressure with...

Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Mortality and Morbidity After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36: 1218–1226. https://doi.org/10.1161/01.STR.0000158925.12740.87 PMID: 18172059

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51: 393–398. https://doi.org/10.1161/01.HYP.0000158925.12740.87 PMID: 18172059

Rakugi H, Ogihara T, Umemoto S, Matsuizaki M, Matsuoka H, Shimada K, et al. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res. 2013; 36: 947–958. https://doi.org/10.1038/hr.2013.63 PMID: 23864054

Peipino CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 289: 2805–2816. https://doi.org/10.1001/jama.289.21.2805 PMID: 14657064

Schrader J, Luders S, Kulischweski A, Hammersen F, Plate K, Berger J, et al. Mortbity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36: 1218–1226. https://doi.org/10.1161/01.STR.0000158925.12740.87 PMID: 18172059

Ogihara T. Practitioner’s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens. 2000; 13: 461–467. https://doi.org/10.1016/S0140-6736(03)14739-3 PMID: 14651507

Andersson OK, Almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998; 317: 167–171. https://doi.org/10.1136/bmj.317.7152.167 PMID: 9665894

Almgren T, Persson B, Wilhelmsen L, Rosengren A, Andersson OK. Stroke and coronary heart disease in treated hypertension—a prospective cohort study over three decades. J Intern Med. 2005; 257: 496–502. https://doi.org/10.1111/j.1365-2796.2005.01497.x PMID: 15910533

Izumi M, Suzuki K, Sakamoto T, Hayashi M. Advantages and limitations of antihypertensive treatment for stroke risk in a general population: the Akita Stroke Registry. Acta Cardiol. 2011; 66: 729–735. https://doi.org/10.1080/ac.66.6.2136956 PMID: 22299383

Benetos A, Thomas F, Bean KE, Guize L. Why cardiovascular mortality is higher in treated hypertensives versus subjects of the same age, in the general population. J Hypertens. 2003; 21: 1635–1640. https://doi.org/10.1073/p00004872-200309000-00011 PMID: 12923394

Gudmundsson LS, Johannsson M, Thorgerisson G, Sigfusson N, Sigvaldason H, Witteman JC. Risk profiles and prognosis of treated and untreated hypertensive men and women in a population-based longitudinal study: the Reykjavik Study. J Hum Hypertens. 2004; 18: 615–622. https://doi.org/10.1038/sj.jhh.1701322 PMID: 15071487

Li C, Engstrom G, Hedblad B, Berglund G, Janzon L. Blood pressure control and risk of stroke: a population-based prospective cohort study. Stroke. 2005; 36: 725–730. https://doi.org/10.1161/01.STR.0000158925.12740.87 PMID: 15746450

Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016; 387: 957–967. https://doi.org/10.1016/S0140-6736(15)0225-8 PMID: 26724178

Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359: 2417–2428. https://doi.org/10.1056/NEJMoao0806182 PMID: 19052124

Ogihara T, Nakao K, Fukui T, Fukiyama K, Ueshima K, Oba K, et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension. 2008; 51: 393–398. https://doi.org/10.1161/01.HYP.0000158925.12740.87 PMID: 18172059

Rakugi H, Ogihara T, Umemoto S, Matsuizaki M, Matsuoka H, Shimada K, et al. Combination therapy for hypertension in patients with CKD: a subanalysis of the Combination Therapy of Hypertension to Prevent Cardiovascular Events trial. Hypertens Res. 2013; 36: 947–958. https://doi.org/10.1038/hr.2013.63 PMID: 23864054

Peipino CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 289: 2805–2816. https://doi.org/10.1001/jama.289.21.2805 PMID: 14657064

Schrader J, Luders S, Kulischweski A, Hammersen F, Plate K, Berger J, et al. Mortbity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). Stroke. 2005; 36: 1218–1226. https://doi.org/10.1161/01.STR.0000158925.12740.87 PMID: 15879332

Ogihara T. Practitioner’s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens. 2000; 13: 461–467. https://doi.org/10.1016/S0140-6736(99)00215-0 PMID: 10826395

Iseki K, Asahi K, Moriyama T, Yamagata K, Tsuruya K, Yoshida H, et al. Risk factor profiles based on estimated glomerular filtration rate and dipstick proteinuria among participants of the Specific Health Check and Guidance System in Japan 2008. Clin Exp Nephrol. 2012; 16: 244–249. https://doi.org/10.1007/s00046-011-0551-9 PMID: 22057582

Yano Y, Sato Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Association of high pulse pressure with proteinuria in subjects with diabetes, prediabetes, or normal glucose tolerance in a large Japanese general population sample. Diabetes Care. 2012; 35: 1310–1315. https://doi.org/10.2337/dc11-2245 PMID: 22474041

Sato Y, Yano Y, Fujimoto S, Konta T, Iseki K, Moriyama T, et al. Glycohemoglobin not as predictive as fasting glucose as a measure of prediabetes in predicting proteinuria. Nephrol Dial Transplant. 2012; 27: 3862–3868. https://doi.org/10.1093/ndt/gfs324 PMID: 22859789
25. Nagai K, Yamagata K, Ohkubo R, Saito C, Asahi K, Izeki K, et al. Annual decline in estimated glomerular filtration rate is a risk factor for cardiovascular events independent of proteinuria. Nephrology (Carlton). 2014; 19: 574–580.

26. Izeki K, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, et al. (2017) Mortality risk among screened subjects of the specific health check and guidance program in Japan 2006–2012. Clin Exp Nephrol. 2017; 21: 978–985. https://doi.org/10.1007/s10157-017-1392-y PMID: 28258498

27. Izeki K, Horio M, Imai E, Matsuo S, Yamagata K. Geographic difference in the prevalence of chronic kidney disease among Japanese screened subjects: Ibaraki versus Okinawa. Clin Exp Nephrol. 2009; 13: 44–49. https://doi.org/10.1007/s10157-009-0080-3 PMID: 18854923

28. Subcommittee Guidelines. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens. 1999; 17: 151–183. PMID: 10067786

29. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305. https://doi.org/10.1056/NEJMoa041031 PMID: 15385666

30. Kuriyama S, Shimazu T, Ohmori K, Kikuchi N, Nakaya N, Nishino Y, et al. Green tea consumption and mortality due to cardiovascular disease, cancer, and all causes in Japan: the Ohsaki study. JAMA. 2006; 296: 1255–1265. https://doi.org/10.1001/jama.296.10.1255 PMID: 16968850

31. Yasui D, Asayama K, Ohkubo T, Kikuya M, Kanno A, Harada A, et al. Stroke risk in treated hypertension based on home blood pressure: the Ohasama study. Am J Hypertens. 2010; 23: 508–514. https://doi.org/10.1038/ajh.2010.15 PMID: 20186131

32. Nakanishi S, Yamada M, Hattori N, Suzuki G. Relationship between HbA1c and mortality in a Japanese population. Diabetologia. 2005; 48: 230–234. https://doi.org/10.1007/s00125-004-1643-9 PMID: 15650819

33. Ueshima H, Choudhury SR, Okayama A, Hayakawa T, Kita Y, et al. Cigarette smoking as a risk factor for stroke death in Japan: NIPPON DATA80. Stroke. 2004; 35: 1836–1841. https://doi.org/10.1161/01.STR.0000131747.84423.74 PMID: 15166389

34. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Ueshima H, et al. The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis. 2006; 184: 143–150. https://doi.org/10.1016/j.atherosclerosis.2005.03.042 PMID: 15913635

35. Yamagata K, Ishida K, Sairenchi T, Takahashi H, Ohba S, Shiigai T, et al. Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int. 2007; 71: 159–166. https://doi.org/10.1038/sj.ki.5002017 PMID: 17136030

36. Blood Pressure Lowering Treatment Trialists C, Ninomiya T, Perkovic V, Turnbull F, Neale B, Barzi F, et al. Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials. BMJ. 2013; 347: f5680. https://doi.org/10.1136/bmj.f5680 PMID: 24082942

37. Kim-Mitsuyama S, Ogawa H, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, et al. An angiotensin II receptor blocker-calcium channel blocker combination prevents cardiovascular events in elderly high-risk hypertensive patients with chronic kidney disease better than high-dose angiotensin II receptor blockade alone. Kidney Int. 2013; 83: 167–176. https://doi.org/10.1038/ki.2012.326 PMID: 23051740